Literature DB >> 18563714

ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells.

Ming Chen1, Jing Ni, Yong Zhang, Mesut Muyan, Shuyuan Yeh.   

Abstract

BACKGROUND: Estrogen receptor alpha (ER alpha) has been reported to be expressed and function in the prostate stromal cells, and numerous evidences indicated that the stromal ER alpha signal pathway plays critical roles in prostate development and cancer. ER alpha requires distinct coregulators for efficient transcriptional regulation. The goal of this study is to examine physical and functional interaction between ER alpha and ERAP75 in the context of prostate stromal cells.
METHOD: Yeast two-hybrid assays were used to screen novel ER alpha interaction proteins. The interaction between ER alpha and ERAP75 was confirmed by mammalian two-hybrid, GST pull-down, and co-immunoprecipitation methods. The interaction motif was examined by site-directed mutagenesis. The effect of ERAP75 on ER alpha transactivation and the expression of ER alpha target genes were determined by luciferase assay and real-time PCR, respectively. RESULT: ER alpha can interact with the C terminus of ERAP75 via its ligand binding domain both in vivo and in vitro. The conserved LXXLL motif within the C terminus of ERAP75 is required for the interaction between ER alpha and ERAP75. ERAP75 can enhance ER alpha transactivation in a dose-dependent manner and up-regulate the expression of the endogenous ER alpha target gene, stromal-derived factor-1 (SDF-1), in the prostate stromal cells.
CONCLUSION: ERAP75 functions as a novel coactivator that can modulate ER alpha function in the prostate stromal cells. The understanding of the mechanism of ER alpha transactivation in prostate stromal cells could possibly help in the development of new strategies to control or treat prostate cancer by targeting its transactivation protein complex. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563714     DOI: 10.1002/pros.20774

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.

Authors:  Renjini Ambika Padmanabhan; Lini Nirmala; Megha Murali; Malini Laloraya
Journal:  Mol Endocrinol       Date:  2011-06-23

2.  Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout mice.

Authors:  Ming Chen; Chiuan-Ren Yeh; Chih-Rong Shyr; Hsiu-Hsia Lin; Jun Da; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2012-05-21       Impact factor: 3.285

3.  Estrogen-induced SDF-1 production is mediated by estrogen receptor-α in female hearts after acute ischemia and reperfusion.

Authors:  Chunyan Huang; Hongmei Gu; Yu Wang; Meijing Wang
Journal:  Surgery       Date:  2011-06-30       Impact factor: 3.982

4.  Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.

Authors:  Defeng Xu; Tzu-Hua Lin; Shaoshun Li; Jun Da; Xing-Qiao Wen; Jiang Ding; Chawnshang Chang; Shuyuan Yeh
Journal:  Cancer Lett       Date:  2011-10-10       Impact factor: 8.679

5.  Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction.

Authors:  Defeng Xu; Qiulu Chen; Yalin Liu; Xingqiao Wen
Journal:  Oncotarget       Date:  2017-11-06

6.  The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.

Authors:  Defeng Xu; Tzu-Hua Lin; Chiuan-Ren Yeh; Max A Cheng; Lu-Min Chen; Chawnshang Chang; Shuyuan Yeh
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

Review 7.  Radiation-induced cardiovascular disease: an overlooked role for DNA methylation?

Authors:  Magy Sallam; Mohammed Abderrafi Benotmane; Sarah Baatout; Pieter-Jan Guns; An Aerts
Journal:  Epigenetics       Date:  2021-01-31       Impact factor: 4.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.